Two months is evidently all it took for the FDA to investigate Vertex’s phase 1/2 trial for its Type 1 diabetes med, lifting a clinical hold that was placed in early May. Vertex said Tuesday that the ...

Vertex Pharmaceuticals says it will pay back all the incentives it has received so far from the state through the quasi-public Massachusetts Life Sciences Center ...

In the world of wristwatches, few designs carry the weight of history like the British field watch from World War II. These ...

What:So far, 2016 has been pretty rough on investors in Vertex Pharmaceuticals. Shares of the cystic fibrosis (CF) leader have fallen drastically in the first half of the year, down more than 29% ...

On Thursday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the ...

As Vertex Pharmaceuticals and British health officials try once again to make a deal on the cystic fibrosis drug Orkambi, patient advocates haven't stopped pushing the two sides to come to terms. A ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has increased its full-year revenue guidance due to continued expected growth in its cystic fibrosis treatment as well as the upcoming launch of gene therapy ...

Vertex Pharmaceuticals’ (NASDAQ:VRTX) investigational non-opioid drug, suzetrigine, has met the primary endpoint in a mid-stage study in people with painful lumbosacral radiculopathy (LSR).

Vertex has picked the two next-generation correctors it will advance into phase 3 cystic fibrosis trials. VX-659 and VX-445 landed spots in experimental triple combinations designed to treat 90% of ...

It's been a tough start to the year for investors in this biopharma. What needs to happen for this company's stock to get back on track? So what: So why has the stock been bludgeoned this year? Here's ...

Vertex's Phase 2 study of suzetrigine met its primary endpoint, reducing pain on the NPRS by -2.02 at Week 12. Post-hoc analysis revealed variability in placebo response, highlighting trial design ...